[
  {
    "ts": null,
    "headline": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
    "summary": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
    "url": "https://finnhub.io/api/news?id=7f3fa4f06245afa0d257ec16d0811730eea82c8c2d132c3f6373abc950aedd9b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749226080,
      "headline": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
      "id": 135088623,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?",
      "url": "https://finnhub.io/api/news?id=7f3fa4f06245afa0d257ec16d0811730eea82c8c2d132c3f6373abc950aedd9b"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference",
    "summary": "BOSTON, June 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s Euro",
    "url": "https://finnhub.io/api/news?id=049db58efaf82dedae89a57c4eec160f3e4fbd6cc2e61ea2310128cf7d77da32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749225600,
      "headline": "Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference",
      "id": 135081402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, June 06, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s Euro",
      "url": "https://finnhub.io/api/news?id=049db58efaf82dedae89a57c4eec160f3e4fbd6cc2e61ea2310128cf7d77da32"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?",
    "summary": "Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=522c2141e8ae046d994d8e888a9b44929754d0de221364ada4d58dfb1472ce44",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749223860,
      "headline": "Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?",
      "id": 135081403,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=522c2141e8ae046d994d8e888a9b44929754d0de221364ada4d58dfb1472ce44"
    }
  },
  {
    "ts": null,
    "headline": "Harbor Long-Term Growers ETF Q1 2025 Commentary",
    "summary": "During Q1, the Harbor Long Term Growers ETF returned -10.09% (at NAV), underperforming the benchmark, the Russell 1000Â® Growth Index, which returned -9.97%.",
    "url": "https://finnhub.io/api/news?id=548090960eab348860d22524fe342b17d9572679f102203ea573fcf9d3152656",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749213120,
      "headline": "Harbor Long-Term Growers ETF Q1 2025 Commentary",
      "id": 135080332,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2067714497/image_2067714497.jpg?io=getty-c-w1536",
      "related": "VRTX",
      "source": "SeekingAlpha",
      "summary": "During Q1, the Harbor Long Term Growers ETF returned -10.09% (at NAV), underperforming the benchmark, the Russell 1000Â® Growth Index, which returned -9.97%.",
      "url": "https://finnhub.io/api/news?id=548090960eab348860d22524fe342b17d9572679f102203ea573fcf9d3152656"
    }
  }
]